According to statistical data, published in New England Journal of Medicine, Republic of Uzbekistan is leading among the countries
of the Central Asia by number of people with excessive weight – they are 44,5 %, and 20,4 % of them are with superobesity. Surgical
bariatric treatment of obesity is the unique method which has proved stable efficiency in reduction of excessive weight at patients with
morbid obesity for a long time. The purpose of this study was evaluation of cardiometabolic risk regression after laparoscopic sleeve
gasterectomy (LSG). There were observed 35 women with morbid obesity. It was established that cardiometabolic risk reduced after
LSG because number of women with average risk by CMDS is reduced in 2 times, with low risk is increased in 1,6 times 12 month
after surgery. Level of proinflammatory cytokine IL-6 and CRP start declining at earlier period after LSG. Volumetric - linear
parameters of heart change synchronously with reduction of excessive weight and is proportional to changes of a surface of a body.
According to statistical data, published in New England Journal of Medicine, Republic of Uzbekistan is leading among the countries
of the Central Asia by number of people with excessive weight – they are 44,5 %, and 20,4 % of them are with superobesity. Surgical
bariatric treatment of obesity is the unique method which has proved stable efficiency in reduction of excessive weight at patients with
morbid obesity for a long time. The purpose of this study was evaluation of cardiometabolic risk regression after laparoscopic sleeve
gasterectomy (LSG). There were observed 35 women with morbid obesity. It was established that cardiometabolic risk reduced after
LSG because number of women with average risk by CMDS is reduced in 2 times, with low risk is increased in 1,6 times 12 month
after surgery. Level of proinflammatory cytokine IL-6 and CRP start declining at earlier period after LSG. Volumetric - linear
parameters of heart change synchronously with reduction of excessive weight and is proportional to changes of a surface of a body.
| № | Havola nomi |
|---|---|
| 1 | 1. Дедов И.И., Мельниченко Г.А., Шестакова М.В., Трошина Е.А., Мазурина Н.В., Шестакова Е.А., Яшков Ю.И., Неймарк А.Е., Бирюкова Е.В., Бондаренко И.З., Бордан Н.С., Дзгоева Ф.Х., Ершова Е.В., Комшилова К.А., Мкртумян А.М., Петунина Н.А., Романцова Т.И., Старостина Е.Г., Стронгин Л.Г., Суплотова Л.А., Фадеев В.В. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых, 3-ий пересмотр (Лечение морбидного ожирения у взрослых) // Ожирение и метаболизм. -2018.-№15(1).-С.53-70. doi: 10.14341/OMET2018153-70. 2. Назиров Ф.Г., Хашимов Ш.Х., Махмудов У.М., Хайбуллина З.Р., Шарапов Н.У., Ходжаева Э.М. Комплексная оценка соматического статуса у больных с морбидным ожирением до и после бариатрического вмешательства // Хирургия Узбекистана, 2020.-№1.-С.3-13. 3. Недогода С.В., Вёрткин А.Л., Наумов А.В., Барыкина И.Н., Саласюк А.С.. Ожирение: критерии, причины, диета, медикаментозное и хирургическое лечение (определение, диагностика; немедикаментозное лечение; лечение ожирения и коморбидной патологии) // Амбулаторный приём.- 2016.-Том 2.-№ 1 (4).-С. 4-33. 4. ChiappettaS., deParvezikbal P., Stier C., Vincenzo Bottino, Rudolf A. Weiner, Runkel N. The role of C-reactive protein after surgery for obesity and metabolic disorders // Surgery for Obesity and Related Diseases.- 2019.-Vol. 11 (16). // doi.org/10.1016/j.soard.2019.10.007. 5. Dedov I.I., Iashkov Yu.I., Ershova E.V. Incretins and its influence on diabetes mellitus 2 type in patients with morbid obesity after bariatric surgery // Obesity and Metabolism.-2012.-№2.-С.3-10. 6. du Plessis J1, van Pelt J, Korf H, Mathieu C, van der Schueren B. Association of Adipose Tissue Inflammation With Histological Severity of Non-alcoholic Fatty Liver Disease // Gastroenterology. -2015.-№ S0016-5085(15).-Р.00771-4. doi: 10.1053/j.gastro.2015.05.044. 7. Fifth IFSO Global Registry Report 2019 // Prepared by Ramos A., Kow L., Brown W., Welbourn R. // IFSO Global Registry. 2019. 8. Guo F, Garvey WT. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the prediction of future diabetes // J. Clin. Endocrinol. Metab. -2015. Vol. 100. N 10. P. 3871–3877. 9. Hadaegh F, Khalili D, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men // Nutr Metab Cardiovasc Dis.-2008.- №19(6).-Р.401-8. doi: 10.1016/j.numecd.2008.09.003. 10. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. The GBD 2015 Obesity Collaborators // N Engl J Med 2017.-№ 377.-Р.13-27. DOI: 10.1056/NEJMoa1614362 11. Jakobsen G.S., Småstuen M.C.,Sandbu R., NordstrandN., Lindberg M., Jens K.H., Hjelmesæth J. Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities// JAMA. 2018.-№319(3).-Р.291-301. doi:10.1001/jama.2017.21055. 12. Li P., Ma B., Gong S. Efficacy and safety of endoscopic sleeve gastroplasty for obesity patients: a meta-analysis // Surg Endosc.-2019. / doi: 10.1007 / s00464-019-06889-6. 13. Mancini M.C. Bariatric surgery - An update for the endocrinologist. // Arq Bras Endocrinol Metabol. 2014 .-№58(9).-Р.875- 88. doi: 10.1590/0004-2730000003413. 14. Marquez M.F., Ayza M.F., Lozano R.B., Morales M.M, Diez J.M., Poujoulet R.B. Gastric Leak After Laparoscopic Sleeve Gastrectomy // Obes Surg .-2010.-№ 20.-Р.1306-1311. 15. Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, Hurme S, Soinio M, Nuutila P,Victorzon M. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric BypassonWeight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial // JAMA. 2018.-№ 16;319(3).-Р.241-254. doi: 10.1001/jama.2017.20313 |